Cambiar Investors’s Gilead Sciences GILD Stock Holding History

Cambiar Investors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-6,325	Closed	-$390K	–	144
2022 Q3	$390K	Sell	6,325 -353	-5%	-$22.3K	0.02%	140
2022 Q2	$413K	Buy	6,678 +2,975	+80%	+$184K	0.02%	139
2022 Q1	$220K	Hold	3,703	–	–	0.01%	139
2021 Q4	$269K	Hold	3,703	–	–	0.01%	143
2021 Q3	$259K	Buy	3,703 +25	+0.7%	+$1.76K	0.01%	140
2021 Q2	$253K	Hold	3,678	–	–	0.01%	145
2021 Q1	$238K	Buy	+3,678	New	+$237K	0.01%	147
2020 Q3	–	Sell	-367,534	Closed	-$28.3M	–	150
2020 Q2	$28.3M	Sell	367,534 -141,865	-28%	-$10.9M	1.3%	33
2020 Q1	$38.1M	Sell	509,399 -156,944	-24%	-$10.8M	1.91%	15
2019 Q4	$43.3M	Buy	666,343 +13,233	+2%	+$862K	1.39%	26
2019 Q3	$41.4M	Buy	+653,110	New	+$42.7M	1.33%	30

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cambiar Investors's GILD Position: Q4 2022 in Review

Cambiar Investors sold out of Gilead Sciences (GILD) in Q4 2022, closing a stake of 6,325 shares — an estimated $390K sold.

Cambiar Investors first reported a position in GILD in Q3 2019 and held it in 11 quarters. The position peaked at $43.3M in Q4 2019. 1,767 funds tracked by Wall St. Rank hold GILD as of Q4 2022.

Cambiar Investors reported no remaining Gilead Sciences position as of Q4 2022 after selling out during the quarter.
Cambiar Investors sold 6,325 Gilead Sciences shares in Q4 2022, an estimated $390K.
Cambiar Investors first reported a position in Gilead Sciences in Q3 2019 and held it in 11 quarters.
Cambiar Investors's Gilead Sciences position peaked at $43.3M in Q4 2019.
1,767 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2022.

Based on Cambiar Investors's 13F filing for Q4 2022, filed 2 Feb 2023.